Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFPROZIL

Form:

17 of 17 products shown

11 general benefit · 6 not a benefit

Other products in the same Health Canada class (J01D, J01DC) — coverage varies; not interchangeable

  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit
  • Cefoxitin (Mefoxin): not a benefit
  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit

1 more in the class list below

Auro-Cefprozil · DIN 02347261 · 125mg/5mL · Oral suspension-75mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cefprozil · DIN 02347261 Manufacturer: Auro Pharma Inc.; listing date 2012-11-27 Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Cefprozil: Formulary list price $7.2750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $7.2750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83267 · Verify on the e-Formulary ↗ (DIN 02347261)

Source record
DIN 02347261: Auro-Cefprozil Raw flags: sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id AUR Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $7.2750; ministry $7.2750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02347261 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83267
Interchangeable products
Cefzil · DIN 02163675 · not recorded Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347261
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · DIN 02329204 · 125mg/5mL · Oral suspension-75mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 02329204 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG/5ML · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Cefprozil: Formulary list price $7.2750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $7.2750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81489 · Verify on the e-Formulary ↗ (DIN 02329204)

Source record
DIN 02329204: Ran-Cefprozil Raw flags: sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id RAN Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $7.2750; ministry $7.2750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02329204 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81489
Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750 Cefzil · DIN 02163675 · not recorded
Shortage status: resolved shortage (ended 2023-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02329204
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Cefprozil · DIN 02347288 · 250mg/5mL · Oral suspension-75mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cefprozil · DIN 02347288 Manufacturer: Auro Pharma Inc.; listing date 2012-11-27 Health Canada: Marketed since 2024-03-01 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Cefprozil: Formulary list price $14.5350/unit (unit not stated in source; not the patient's cost)

Ministry pays: $14.5350 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83268 · Verify on the e-Formulary ↗ (DIN 02347288)

Source record
DIN 02347288: Auro-Cefprozil Raw flags: sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id AUR Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $14.5350; ministry $14.5350 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02347288 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83268
Interchangeable products
Cefzil · DIN 02163683 · not recorded Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347288
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · DIN 02293579 · 250mg/5mL · Oral suspension-75mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 02293579 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-09-04 Health Canada: Marketed since 2025-10-31 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG/5ML · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Cefprozil: Formulary list price $14.5350/unit (unit not stated in source; not the patient's cost)

Ministry pays: $14.5350 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77893 · Verify on the e-Formulary ↗ (DIN 02293579)

Source record
DIN 02293579: Ran-Cefprozil Raw flags: sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id RAN Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $14.5350; ministry $14.5350 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293579 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77893
Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350 Cefzil · DIN 02163683 · not recorded
Shortage status: resolved shortage (ended 2023-10-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293579
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · DIN 02293528 · 250mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 02293528 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06 Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Cefprozil: Formulary list price $1.7374/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7374 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77887 · Verify on the e-Formulary ↗ (DIN 02293528)

Source record
DIN 02293528: Ran-Cefprozil Raw flags: sec3=Y Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id RAN Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $1.7374; ministry $1.7374 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293528 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77887
Interchangeable products
Cefzil · DIN 02163659 · not recorded
Shortage status: resolved shortage (ended 2022-12-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293528
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Cefprozil · DIN 02347253 · 500mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cefprozil · DIN 02347253 Manufacturer: Auro Pharma Inc.; listing date 2012-04-24 Health Canada: Marketed since 2019-01-23 · brand AURO-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Cefprozil: Formulary list price $2.0038/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0038 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83266 · Verify on the e-Formulary ↗ (DIN 02347253)

Source record
DIN 02347253: Auro-Cefprozil Raw flags: sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $2.0038; ministry $2.0038 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02347253 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83266
Interchangeable products
Cefzil · DIN 02163667 · not recorded Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: resolved shortage (ended 2025-03-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02347253
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · DIN 02293536 · 500mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 02293536 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-06-06 Health Canada: Marketed since 2025-06-18 · brand SPC-CEFPROZIL · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Cefprozil: Formulary list price $2.0038/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0038 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77888 · Verify on the e-Formulary ↗ (DIN 02293536)

Source record
DIN 02293536: Ran-Cefprozil Raw flags: sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id RAN Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $2.0038; ministry $2.0038 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293536 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77888
Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038 Cefzil · DIN 02163667 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293536
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Cefprozil · PIN 09858332 · 125mg/5mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cefprozil · DIN 09858332 Manufacturer: Auro Pharma Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Auro-Cefprozil: Formulary list price $9.7000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.7000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858332)

Source record
DIN 09858332: Auro-Cefprozil Raw flags: sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id AUR Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $9.7000; ministry $9.7000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858332 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Cefzil · DIN 09857358 · not recorded Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858332
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · PIN 09857356 · 125mg/5mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 09857356 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Ran-Cefprozil: Formulary list price $9.7000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.7000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857356)

Source record
DIN 09857356: Ran-Cefprozil Raw flags: sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id RAN Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $9.7000; ministry $9.7000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857356 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000 Cefzil · DIN 09857358 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857356
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Cefprozil · PIN 09858333 · 250mg/5mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Cefprozil · DIN 09858333 Manufacturer: Auro Pharma Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Auro-Cefprozil: Formulary list price $19.3800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.3800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858333)

Source record
DIN 09858333: Auro-Cefprozil Raw flags: sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id AUR Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.3800; ministry $19.3800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858333 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Cefzil · DIN 09857359 · not recorded Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858333
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Cefprozil · PIN 09857365 · 250mg/5mL · Oral suspension-100mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Cefprozil · DIN 09857365 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Ran-Cefprozil: Formulary list price $19.3800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.3800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857365)

Source record
DIN 09857365: Ran-Cefprozil Raw flags: sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id RAN Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.3800; ministry $19.3800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857365 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800 Cefzil · DIN 09857359 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857365
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefzil · PIN 09857358 · 125mg/5mL · Oral suspension-100mL Pk

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 09857358 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857358)

Source record
DIN 09857358: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228123; group id 40; item number 0081; lccId None; manufacturer id BQU Source form: Oral Susp-100mL Pk; strength: 125mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857358 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858332 · $9.7000 Ran-Cefprozil · DIN 09857356 · $9.7000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857358
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefzil · PIN 09857359 · 250mg/5mL · Oral suspension-100mL Pk

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 09857359 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2010-06-14 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857359)

Source record
DIN 09857359: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228124; group id 40; item number 0082; lccId None; manufacturer id BQU Source form: Oral Susp-100mL Pk; strength: 250mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857359 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Auro-Cefprozil · DIN 09858333 · $19.3800 Ran-Cefprozil · DIN 09857365 · $19.3800
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857359
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefzil · DIN 02163675 · 125mg/5mL · Oral suspension-75mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.Discontinued 2018-01-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 02163675 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2018-01-22 · brand CEFZIL POWDER FOR ORAL SUSPENSION-125MG/5ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 125 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19227 · Verify on the e-Formulary ↗ (DIN 02163675)

Source record
DIN 02163675: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228083; group id 40; item number 0083; lccId None; manufacturer id BQU Source form: Oral Susp-75mL Pk; strength: 125mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163675 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19227
Interchangeable products
Auro-Cefprozil · DIN 02347261 · $7.2750 Ran-Cefprozil · DIN 02329204 · $7.2750
Shortage status: discontinued (2017-12-29, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163675
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-01-22 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163683 · 250mg/5mL · Oral suspension-75mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.Discontinued 2017-09-14 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 02163683 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-09-14 · brand CEFZIL POWDER FOR ORAL SUSPENSION-250 MG/ 5 ML · ATC J01DC10 CEFPROZIL · form Powder for suspension · route Oral · ingredients CEFPROZIL 250 MG/5ML · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19226 · Verify on the e-Formulary ↗ (DIN 02163683)

Source record
DIN 02163683: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228084; group id 40; item number 0084; lccId None; manufacturer id BQU Source form: Oral Susp-75mL Pk; strength: 250mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163683 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19226
Interchangeable products
Auro-Cefprozil · DIN 02347288 · $14.5350 Ran-Cefprozil · DIN 02293579 · $14.5350
Shortage status: discontinued (2017-08-23, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163683
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163659 · 250mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.Discontinued 2017-08-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 02163659 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-08-02 · brand CEFZIL TABLETS - 250MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 250 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19229 · Verify on the e-Formulary ↗ (DIN 02163659)

Source record
DIN 02163659: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228085; group id 40; item number 0085; lccId None; manufacturer id BQU Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163659 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19229
Interchangeable products
Ran-Cefprozil · DIN 02293528 · $1.7374
Shortage status: discontinued (2017-06-30, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163659
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-08-02 — choose a marketed DIN from the same-category list.

Cefzil · DIN 02163667 · 500mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.Discontinued 2017-08-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefzil · DIN 02163667 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-12-19 Health Canada: Cancelled post market since 2017-08-22 · brand CEFZIL TABLETS - 500MG · ATC J01DC10 CEFPROZIL · form Tablet · route Oral · ingredients CEFPROZIL 500 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Cefzil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19228 · Verify on the e-Formulary ↗ (DIN 02163667)

Source record
DIN 02163667: Cefzil Raw flags: notABenefit=Y, sec3=Y Item: 081228086; group id 40; item number 0086; lccId None; manufacturer id BQU Source form: Tab; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163667 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19228
Interchangeable products
Auro-Cefprozil · DIN 02347253 · $2.0038 Ran-Cefprozil · DIN 02293536 · $2.0038
Shortage status: discontinued (2017-07-31, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163667
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-08-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE SPC-Cefprozil (cefprozil) is indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Upper Respiratory Tract Pharyngitis / tonsillitis caused by group A ß-hemolytic (GABHS) Streptococcus pyogenes. Substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present, although no case was reported during its evaluation in over 978 pediatric and 831 adult patients in controlled clinical trials. Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis. Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, (beta-lactamase positive and negative strains), and Moraxella (Branhamella) catarrhalis. Skin And Skin Structure Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Urinary Tract Uncomplicated urinary tract infections (including acute cystitis) caused by Escherichia coli, Pr SPC-Cefprozil – Product Monograph … https://pdf.hres.ca/dpd_pm/00080833.PDF PM date: JUN 18, 2025 Source product: SPC-CEFPROZIL; DIN 02293528; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Cefzil · DIN 02163675 Shortage status: discontinued (2017-12-29, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163675

Check this DIN again

Cefzil · DIN 02163683 Shortage status: discontinued (2017-08-23, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163683

Check this DIN again

Cefzil · DIN 02163659 Shortage status: discontinued (2017-06-30, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163659

Check this DIN again

Cefzil · DIN 02163667 Shortage status: discontinued (2017-07-31, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163667

Check this DIN again

Other review policies

For Cefzil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026